主题:The Discovery and Development of A Clinical Candidate WX-081 for MDR-Tuberculosis Therapy
报告人：Dr. Charles Z. Ding
VP of Department of Medicinal Chemistry WuXi AppTec, Shanghai, China
时间：2016年11月3日(星期四)下午2:00
地点：化学楼五楼学术报告厅
Lecture Abstract:
Multidrug-resistant tuberculosis (MDR-TB), defined as respiratory lung disease caused by strains ofMycobacterium tuberculosisresistant to at least isoniazid and rifampicin, threatens to erode progress in the global control of TB. Drug resistance may worsen further with the emergence of resistance to at least one of the injectable agents (amikacin, kanamycin, capreomycin) or to fluoroquinolones (deemed pre-extensively drug-resistant (pre-XDR)-TB by some authors) or both (extensively drug-resistant (XDR)-TB). It has been reported that only∼50% of patients with MDR-TB respond favorably to current treatment. With soaring incidence and mortality rates worldwide and frequent outbreaks of drug-resistant tuberculosis, there is a pressing need for new agents/therapies for MDR-tuberculosis. CISEN and WuXi have launched TB project, aiming to develop novel, effective, safe, anti-TB agent to fight MDR-tuberculosis. In this seminar, we will present discovery of WX081 a second generation ATPase inhibitor (bedaquiline-like) anti-tuberculosis agent, its SAR study, its anti MDR-tuberculosis profile, in vivo efficacy, safety etc, leading to nomination of our clinical candidate.
Speaker Introduction:
Dr. Charles Z. Ding is Vice President of Medicinal Chemistry at WuXi AppTec (Shanghai) and joined WuXi in 2010. He has played an important role in successful establishment of the Domestic Discovery Service Unit (DDSU) that was founded in 2014. Under Dr. Ding's supervision, DDSU Wuhan team has achieved successes in various 1.1 class new drug candidates' discoveries and developments in many therapeutic areas including oncology, hepatitis B, cardiovascular disease, and antibiotics. We have filed five Investigational New Drug (IND) application to China FDA. Dr. Ding has been elected to ‘the Thousand Talents Plan’ program, and he is a member of American Chemical Society, American Association for Advancement of Science, American Society of Microbiology. Dr. Ding received his B.S. degree in Chemistry from Lanzhou University and earned his Ph.D. from State University of New York at Buffalo, U.S.A under the guidance of Professor Joseph J. Tufariello. Then, he pursued his postdoctoral studies with Professor Richard B. Silverman at Northwestern University. Dr. Ding has worked for Bristol-Myers Squibb for 11 years. Before joining WuXi AppTec, he served as director of Medicinal Chemistry at Anacor Pharmaceuticals, Inc., and Cumbre Pharmaceuticals, Inc. for total 8 years. He has authored or co-authored more than 60 peer reviewed publications and more than 50 patents and applications worldwide.
